Edelweiss: Cancer Open Access (ISSN: 2689-6737)

Edelweiss: Cancer Open Access (ISSN: 2689-6737)

Explore journal overview, editorial leadership, indexing, articles in press, latest published work, and highlights from previous issues.

Edelweiss: Cancer Open Access (ISSN: 2689-6737)

Chemotherapy

Edelweiss: Cancer Open Access journal | Chemotherapy Research articles | Open access hormonal therapies Articles

Chemotherapy is a type of cancer treatment that uses chemotherapeutic agents. Chemotherapy may be given with a curative intent. it may aim to prolong life or to reduce symptoms. the use of drugs (whether chemotherapy, hormonal therapy or targeted therapy) constitutes systemic therapy for cancer in that they are introduced into the blood stream and are therefore in principle able to address cancer at any anatomic location in the body.

Chemotherapy excludes more selective agents that block extracellular signals. The development of therapies with specific molecular or genetic targets, which inhibit growth-promoting signals from classic endocrine hormones are now called hormonal therapies. By contrast, other inhibitions of growth-signals like those associated with receptor tyrosine kinases are referred to as targeted therapy.

Edelweiss: Cancer Open Access is an open access journal which aims to publish most complete and genuine source of information in the form of short commentary, mini review, case report, related, but not limited to above areas and making them available freely through online without any subscriptions and restrictions to researches worldwide

Researchers, authors, reviewers, and readers can use this page to find journal resources connected with Chemotherapy, including published articles, related academic topics, current issue content, archive material, and manuscript submission information.

Related Articles

More Topics in This Journal

Edelweiss: Cancer Open Access (ISSN: 2689-6737)

Subscribe for updates

Subscribe

to get latest updates.


  Life Science

  Health Science

  Chemical Science


Subscribe